AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26756117 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 and type 2 diabetes patients
Number of subjects: 0
Study 26756119 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV subjects with long-duration antiretroviral use
Number of subjects: 18
Study 26756119 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV subjects
Number of subjects: 18
Study 26756119 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV subjects with excess DCAT
Number of subjects: 18
Study 26756872 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal microchimerism screening in lymph nodes
Number of subjects: 6
Study 26756872 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal microchimerism screening in infants' peripheral blood
Number of subjects: 6
Study 26757199 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 26757728 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Intervention
Number of subjects: 88
Study 26757728 — intervention group
Group type: COMPARATOR
Intervention: Active Control (psycho-education and relaxation techniques)
Number of subjects: 88
Study 26757786 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 13662
Study 26757786 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-recommended therapies
Number of subjects: 13662
Study 26757786 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital mortality
Number of subjects: 13662
Study 26757786 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital major adverse cardiac and cerebrovascular events
Number of subjects: 13662
Study 26757786 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson score ≥2 in patients treated with PCI
Number of subjects: 13662
Study 26758264 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative risk score for potentially preventable 'medical' complications
Number of subjects: 8373
Study 26758264 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative characteristics associated with potentially preventable 'medical' complications
Number of subjects: 8373
Study 26758264 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ≥ 2 of the following characteristics: age ≥ 80 years, anticoagulant therapy, pulmonary disease, pharmacologically treated psychiatric disorder, anaemia, and walking aids
Number of subjects: 8373
Study 26758264 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical intervention leading to 25% reduction in potentially preventable 'medical' complications
Number of subjects: 8373
Study 26758264 — intervention group
Group type: EXPERIMENTAL
Intervention: THA, use of walking aids and cardiac disease
Number of subjects: 8373
Study 26758264 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative identification of patients at high risk of preventable 'medical' complications
Number of subjects: 8373
Study 26758536 — intervention group
Group type: EXPERIMENTAL
Intervention: SPARCS
Number of subjects: 93
Study 26758536 — intervention group
Group type: COMPARATOR
Intervention: Pelli-Robson (PR)
Number of subjects: 93
Study 26758543 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Angiography (CAG) performed
Number of subjects: 798
Study 26758543 — intervention group
Group type: COMPARATOR
Intervention: No Coronary Angiography (CAG) performed
Number of subjects: 798
Study 26758543 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivessel Coronary Artery Disease (CAD) with CAG performed
Number of subjects: 798
Study 26758543 — intervention group
Group type: COMPARATOR
Intervention: Non-performance of CAG
Number of subjects: 798
Study 26758560 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA analysis using next-generation sequencing for 50 cancer genes
Number of subjects: 334
Study 26758560 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA analysis
Number of subjects: 334
Study 26758879 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg daily for 2 years
Number of subjects: 42
Study 26759718 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (MT) for 10 weeks
Number of subjects: 64
Study 26759718 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal effectiveness skills training (IE) for 10 weeks
Number of subjects: 64
Study 26759992 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of antipsychotic medication (N=46)
Number of subjects: 68
Study 26759992 — intervention group
Group type: COMPARATOR
Intervention: Maintenance on prescribed antipsychotic medication (N=22)
Number of subjects: 68
Study 26759992 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group of relapsed individuals (N=38)
Number of subjects: 68
Study 26761266 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 151
Study 26761269 — intervention group
Group type: EXPERIMENTAL
Intervention: Seminal plasma-derived IgG
Number of subjects: 11
Study 26761269 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched IgG
Number of subjects: 11
Study 26761707 — intervention group
Group type: EXPERIMENTAL
Intervention: H3N2 influenza challenge virus
Number of subjects: 0
Study 26761707 — intervention group
Group type: EXPERIMENTAL
Intervention: Different inoculum titres of H3N2 virus
Number of subjects: 0
Study 26761784 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine-based anticancer regimens
Number of subjects: 1463
Study 26762240 — intervention group
Group type: EXPERIMENTAL
Intervention: RVLS < |13|%
Number of subjects: 211
Study 26762240 — intervention group
Group type: EXPERIMENTAL
Intervention: RVLS > |13|%
Number of subjects: 211
Study 26762240 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest RVLS < |13|%
Number of subjects: 211
Study 26762240 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress RVLS < |14|%
Number of subjects: 211
Study 26762240 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress RVLS < |14|% after adjustment for rest RVLS
Number of subjects: 211
Study 26762240 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest RVLS
Number of subjects: 211
Study 26762316 — intervention group
Group type: EXPERIMENTAL
Intervention: i-Scan endoscopy (SE)
Number of subjects: 138
Study 26762363 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose inactivated influenza vaccine
Number of subjects: 0
Study 26762363 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose inactivated influenza vaccine
Number of subjects: 0
Study 26762363 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemagglutination inhibition assay
Number of subjects: 0
Study 26762363 — intervention group
Group type: EXPERIMENTAL
Intervention: Virus neutralization test titers
Number of subjects: 0
Study 26762363 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-linked lectin assay for antineuraminidase N2 antibodies
Number of subjects: 0
Study 26762403 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic brain health self-management information
Number of subjects: 900
Study 26762403 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific, more intensive interventions (pilot studies)
Number of subjects: 900
Study 26762579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 100 mg daily
Number of subjects: 81
Study 26763281 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial hemorrhage 2 days post MI
Number of subjects: 286
Study 26763281 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial hemorrhage
Number of subjects: 286
Study 26763281 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular obstruction
Number of subjects: 286
Study 26763495 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 228
Study 26763495 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 228
Study 26763552 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum AMH levels measured using Beckman Coulter Gen II assay
Number of subjects: 1590
Study 26763552 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of AMH with other clinical markers
Number of subjects: 1590
Study 26764356 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (50 mg/kg per day on days 3 and 4 after transplantation)
Number of subjects: 43
Study 26764356 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide
Number of subjects: 43
Study 26764881 — intervention group
Group type: EXPERIMENTAL
Intervention: Descemet membrane endothelial keratoplasty
Number of subjects: 66
Study 26765643 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 5142
Study 26765643 — intervention group
Group type: COMPARATOR
Intervention: Standard anticoagulation therapy
Number of subjects: 5142
Study 26765645 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (10 mg per day for 10 days)
Number of subjects: 25
Study 26765812 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 restriction for 4 weeks
Number of subjects: 0
Study 26765812 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine supplementation in subjects with chronically low vitamin B6 status
Number of subjects: 0
Study 26765812 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 deficiency
Number of subjects: 0
Study 26765812 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical whole body transsulfuration flux
Number of subjects: 0
Study 26765937 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation for HIV-positive recipients with MELD ≥ 15
Number of subjects: 63
Study 26765937 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation for HIV-positive recipients with MELD < 15
Number of subjects: 63
Study 26765937 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplantation for HIV-positive recipients
Number of subjects: 63
Study 26765937 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplantation for HIV-positive recipients (unmatched analysis)
Number of subjects: 63
Study 26765937 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplantation for HIV-positive recipients (risk-matched analysis)
Number of subjects: 63
Study 26765937 — intervention group
Group type: COMPARATOR
Intervention: Comparison with HIV-negative controls
Number of subjects: 63
Study 26766736 — intervention group
Group type: EXPERIMENTAL
Intervention: PI3K/AKT/mTOR inhibitors
Number of subjects: 35
Study 26766736 — intervention group
Group type: EXPERIMENTAL
Intervention: Large microRNA cluster on chr19q13.42
Number of subjects: 35
Study 26766736 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 35
Study 26766751 — intervention group
Group type: EXPERIMENTAL
Intervention: EDIPPP outreach and education model
Number of subjects: 337
Study 26766959 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 255
Study 26766959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 26767310 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery on the lower gastrointestinal tract
Number of subjects: 604
Study 26767310 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of adhesions in the operative area
Number of subjects: 604
Study 26767709 — intervention group
Group type: COMPARATOR
Intervention: Pipeline Embolization Device alone
Number of subjects: 793
Study 26767709 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipeline Embolization Device with concurrent coil embolization
Number of subjects: 793
Study 26768369 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal formulations of amphotericin B
Number of subjects: 0
Study 26768369 — intervention group
Group type: COMPARATOR
Intervention: Commercial amphotericin B lipid products
Number of subjects: 0
Study 26768570 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma and supportive care
Number of subjects: 0
Study 26768570 — intervention group
Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 0
Study 26768772 — intervention group
Group type: EXPERIMENTAL
Intervention: ED-initiated palliative care consultation
Number of subjects: 136
Study 26768772 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 136
Study 26769776 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative physical activity level 3 or 4 (more active)
Number of subjects: 220
Study 26769776 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy versus partial mastectomy
Number of subjects: 220
Study 26769776 — intervention group
Group type: COMPARATOR
Intervention: Axillary lymph node dissection versus sentinel node biopsy
Number of subjects: 220
Study 26769776 — intervention group
Group type: COMPARATOR
Intervention: Preoperative physical activity (inactive vs more active)
Number of subjects: 220
Study 26770032 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated zoster vaccine (ZOSTAVAX™, Merck & Co., Inc.)
Number of subjects: 180
Study 26770070 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred information intervention consisting of four sessions with children's nurses trained in the intervention method.
Number of subjects: 0
Study 26770070 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 26770827 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored training based on motivational interviewing (MI) techniques
Number of subjects: 45
Study 26770827 — intervention group
Group type: COMPARATOR
Intervention: Pre-training measurements
Number of subjects: 45
Study 26770827 — intervention group
Group type: COMPARATOR
Intervention: Post-training measurements
Number of subjects: 45
Study 26771213 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsynonymous variant rs181206 in IL27
Number of subjects: 12025
Study 26771213 — intervention group
Group type: EXPERIMENTAL
Intervention: rs16969968 in CHRNA5
Number of subjects: 12025
Study 26771213 — intervention group
Group type: EXPERIMENTAL
Intervention: AGER, MMP3, SERPINA1 variants
Number of subjects: 12025
Study 26771213 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression datasets
Number of subjects: 12025
Study 26771550 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine
Number of subjects: 2
Study 26771550 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab
Number of subjects: 2
Study 26771572 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (Celexa)
Number of subjects: 0
Study 26771742 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise session
Number of subjects: 24
Study 26771742 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous exercise session
Number of subjects: 24
Study 26771742 — intervention group
Group type: COMPARATOR
Intervention: Control session
Number of subjects: 24
Study 26771810 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib (Cfz)
Number of subjects: 62
Study 26772390 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced syphilis screening intervention with standing orders for syphilis serological testing during HIV viral load testing every 3-6 months
Number of subjects: 3100
Study 26772390 — intervention group
Group type: COMPARATOR
Intervention: Current provider-initiated syphilis testing practice
Number of subjects: 3100
Study 26772443 — intervention group
Group type: EXPERIMENTAL
Intervention: Collateral flow index (CFI) in the coronary artery (CA)
Number of subjects: 100
Study 26772443 — intervention group
Group type: EXPERIMENTAL
Intervention: Collateral flow index (CFI) in the renal artery (RA)
Number of subjects: 100
Study 26772443 — intervention group
Group type: EXPERIMENTAL
Intervention: Collateral flow index (CFI) in the left superficial femoral artery (SFA)
Number of subjects: 100
Study 26772443 — intervention group
Group type: EXPERIMENTAL
Intervention: Collateral flow index (CFI) in the left subclavian artery (SCA)
Number of subjects: 100
Study 26772443 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between CA and SFA CFI
Number of subjects: 100
Study 26772443 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between left SFA and left SCA CFI
Number of subjects: 100
Study 26772734 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg/day on a 4-week-on, 2-week-off schedule)
Number of subjects: 230
Study 26772801 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECIS-2 criteria rating for primary analysis
Number of subjects: 5
Study 26772801 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECIS-2 criteria rating for recruitment
Number of subjects: 5
Study 26772801 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECIS-2 criteria rating for eligibility
Number of subjects: 5
Study 26772801 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECIS-2 criteria rating for setting
Number of subjects: 5
Study 26772801 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECIS-2 criteria rating for follow-up
Number of subjects: 5
Study 26772801 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECIS-2 criteria rating for primary outcome
Number of subjects: 5
Study 26772801 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECIS-2 criteria rating for organization
Number of subjects: 5
Study 26772801 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECIS-2 criteria rating for flexibility of intervention delivery
Number of subjects: 5
Study 26772801 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECIS-2 criteria rating for flexibility of intervention adherence
Number of subjects: 5
Study 26772801 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrater agreement for four trials
Number of subjects: 5
Study 26772801 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraclass correlation coefficient for ratings
Number of subjects: 5
Study 26772812 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m², 60 min, d 1) and oxaliplatin (80 mg/m², 120 min, d 2) in 21-day cycles for up to 8 cycles
Number of subjects: 44
Study 26772812 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel and oxaliplatin
Number of subjects: 44
Study 26773458 — intervention group
Group type: EXPERIMENTAL
Intervention: Network-informed clustering of blood gene expression
Number of subjects: 229
Study 26773712 — intervention group
Group type: EXPERIMENTAL
Intervention: (131) I-MIBG therapy at a dose of 0.67 GBq (18 mCi)/kg/dose
Number of subjects: 10
Study 26773712 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolling lead shields and radiation safety procedures
Number of subjects: 10
Study 26773712 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid bioassay scans on medical personnel
Number of subjects: 10
Study 26773712 — intervention group
Group type: EXPERIMENTAL
Intervention: Contamination surveys
Number of subjects: 10
Study 26774073 — intervention group
Group type: EXPERIMENTAL
Intervention: High neck circumference (NC) in males
Number of subjects: 116
Study 26774073 — intervention group
Group type: COMPARATOR
Intervention: Low neck circumference (NC) in males
Number of subjects: 116
Study 26774073 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of NC and BMI percentile
Number of subjects: 116
Study 26774073 — intervention group
Group type: COMPARATOR
Intervention: BMI percentile alone
Number of subjects: 116
Study 26774243 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Number of subjects: 241
Study 26774243 — intervention group
Group type: COMPARATOR
Intervention: Artesunate plus mefloquine
Number of subjects: 241
Study 26774243 — intervention group
Group type: COMPARATOR
Intervention: Single low-dose primaquine
Number of subjects: 241
Study 26774555 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat 20 mg orally 3 times weekly with letrozole 2.5 mg daily
Number of subjects: 12
Study 26774555 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat 30 mg orally 3 times weekly with letrozole 2.5 mg daily
Number of subjects: 12
Study 26774947 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekday adherence
Number of subjects: 255
Study 26774947 — intervention group
Group type: COMPARATOR
Intervention: Weekend adherence
Number of subjects: 255
Study 26774947 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge drinking at baseline
Number of subjects: 255
Study 26774947 — intervention group
Group type: EXPERIMENTAL
Intervention: Time on study
Number of subjects: 255
Study 26775292 — intervention group
Group type: EXPERIMENTAL
Intervention: BioQC testing at 20 W and 70 W
Number of subjects: 129
Study 26775292 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite z-score analysis
Number of subjects: 129
Study 26777085 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal levodopa-carbidopa intestinal gel (LCIG) infusion
Number of subjects: 15
Study 26777228 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-TULSA treatment
Number of subjects: 30
Study 26777916 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a genetic alteration
Number of subjects: 17664
Study 26777916 — intervention group
Group type: COMPARATOR
Intervention: Absence of a genetic alteration
Number of subjects: 17664
Study 26778344 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 26778412 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-530 with paritaprevir/ritonavir and ribavirin
Number of subjects: 10
Study 26778949 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-prandial state (after lunch)
Number of subjects: 15
Study 26778949 — intervention group
Group type: COMPARATOR
Intervention: Pre-prandial state (before lunch)
Number of subjects: 15
Study 26778949 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose gustatory stimulation
Number of subjects: 15
Study 26778949 — intervention group
Group type: EXPERIMENTAL
Intervention: Hunger sensation, wanting, liking, and perception of solution's intensity
Number of subjects: 15
Study 26780395 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate (2 capsules of 220 mg each per day for 3 months)
Number of subjects: 60
Study 26780484 — intervention group
Group type: EXPERIMENTAL
Intervention: Tabalumab (BAFF inhibitor) 240-mg SC at Week 0 followed by 120-mg SC monthly for 5 additional months.
Number of subjects: 18
Study 26780484 — intervention group
Group type: EXPERIMENTAL
Intervention: Tabalumab (BAFF inhibitor)
Number of subjects: 18
Study 26780948 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART program
Number of subjects: 3722
Study 26780948 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3722
Study 26781262 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-arm mesh with titanium coating (TILOOP(®) Total 6)
Number of subjects: 289
Study 26781431 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral density by dual-energy X-ray absorptiometry (DXA) at forearm (FA)
Number of subjects: 89